AstraZeneca issues updated Phase 3 trial data

A healthcare worker prepares to inject an AstraZeneca coronavirus disease (COVID-19) vaccine.

Eloisa Lopez

AstraZeneca issued updated Phase 3 trial data for its Covid-19 vaccine on Wednesday after facing criticism earlier this week over a preliminary report.

The company now says its vaccine is 76% effective in protecting against symptomatic cases of virus. A release earlier this week reported a symptomatic efficacy rate of 79%. Both reports from the company indicated the vaccine is 100% effective against severe disease and hospitalization.

This is breaking news. Please check back for updates.

Source link